EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice

Clinical Cancer Research

Volumn 17, Issue 5, 2011, Pages 1033-1043

  Shir, Alexei ^a   Ogris, Manfred ^b   Roedl, Wolfgang ^b   Wagner, Ernst ^b   Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; DOUBLE STRANDED RNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MACROGOL; MELITTIN; POLYETHYLENEIMINE; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISSEMINATED CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; MELITTEN; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; POLY I-C; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, DOUBLE-STRANDED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952261244     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1140     Document Type: Article

References (27)

1. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177-84.
2. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med 2006;3:e6.
3. Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJ. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 1996;56:3859-61. (Pubitemid 26284726)
4. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002;13:1971-80. (Pubitemid 35341038)
5. Huang H, Xiang J. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors. Int J Cancer 2004; 109:817-25. (Pubitemid 38500737)
6. Kruse N, Moriabadi NF, Toyka KV, Rieckmann P. Characterization of early immunological responses in primary cultures of differentially activated human peripheral mononuclear cells. J Immunol Methods 2001;247:131-9. (Pubitemid 32063087)
7. Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 2008;109:174-81.
8. Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets 2008;8:124-31.
9. Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Res 1995;55: 4988-94.
10. Mori S, Jewett A, Murakami-Mori K, Cavalcanti M, Bonavida B. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother 1997;44:282-90. (Pubitemid 27306906)
11. Gattoni A, Parlato A, Vangieri B, Bresciani M, Derna R. Interferongamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts). Clin Ter 2006;157:457-68. (Pubitemid 44905230)
12. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006;97:439-47. (Pubitemid 43811583)
13. Liu TF, Cohen KA, Ramage JG, Willingham MC, Thorburn AM, Frankel AE. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res 2003; 63:1834-7. (Pubitemid 36460845)
14. Paludan SR. Synergistic action of pro-inflammatory agents: cellular and molecular aspects. J Leukoc Biol 2000;67:18-25. (Pubitemid 30046813)
15. Talmadge JE. Synergy in the toxicity of cytokines: preclinical studies. Int J Immunopharmacol 1992;14:383-90.
16. Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003;33:1030-40. (Pubitemid 36546691)
17. Lorber MI, Wilson JH, Robert ME, Schechner JS, Kirkiles N, Qian HY, et al. Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. Transplantation 1999;67:897-903. (Pubitemid 29169137)
18. King M, Pearson T, Shultz LD, Leif J, Bottino R, Trucco M, et al. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-SCID mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 2008;126:303-14.
19. Tai HC, Tu CF, Lee JM, Ho LL, Tseng YL, Chou NK, et al. Long-term survival of HLA-DR15+ pig skin in SCID mice after reconstitution with human peripheral blood mononuclear cells and under short-term immunosuppression. Transplant Proc 2008;40:570-3.
20. Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol 2009;91:175-82.
21. Salazar AM, Levy HB, Ondra S, Kende M, Scherokman B, Brown D, et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 1996;38:1096-103; discussion 1103-4.
22. Bai A, Higham E, Eisen HN, Wittrup KD, Chen J. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A 2008;105:13003-8.
23. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80. (Pubitemid 37040391)
24. Coussens LM, Werb Z. Inflammatory cells and cancer: think different!J Exp Med 2001;193:F23-6.
25. Rosenberg SA. Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci U S A 2008;105:12643-4.
26. Fujimura T, Nakagawa S, Ohtani T, Ito Y, Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol 2006;36:3371-80. (Pubitemid 44932738)
27. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007;109:4698-707. (Pubitemid 46827761)